OxyContin Abuse Deterrent Formulation Voted Beneficial By FDA Panel, But Questions Remain

 
• By Brenda Sandburg
  
Pills
FDA advisory committee gives mixed reviews to OxyContin ADF postmarketing studies • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers